…
Enlitic, Inc. operates in the healthcare sector in the United States, Europe, and Japan. The company uses artificial intelligence (AI) to develop software products that manage medical imaging data in radiology, such as magnetic resonance imaging, computed tomography scans, X-ray, and ultrasound images. Its healthcare data solutions include ENDEX, a platform that uses AI to standardize new and historical medical image data descriptions; ENCOG, an AI enabled data anonymization solution designed to de-identify protected health information from medical imaging data; and Migratek, an AI-enabled data migration solution, as well as routing services. The company provides its solutions to radiologists, IT professionals, executives, and researchers; and training services to PACS administrators, IT supervisors, system administrators, radiologists, and technologists. The company was formerly known as You Partners, Inc. Enlitic, Inc. was incorporated in 2014 and is based in Loveland, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Enlitic Inc is an Australia-listed company developing artificial intelligence for medical imaging to assist clinicians with detection and workflow prioritization. Long-term growth drivers include rising AI adoption in healthcare, increasing diagnostic demand, and software scalability that may appeal to investors seeking exposure to clinical AI.
Key risks are the need for robust clinical evidence and regulatory clearance, strong competition from established medical-imaging vendors and other AI firms, and funding and commercialization challenges typical of small health-technology companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | -13.34M | -15.25M | -15.55M | -25.04M |
| Net income | -13.37M | -15.24M | -15.55M | -25.04M |
| Selling general administrative | 12.17M | 15.50M | 14.39M | 16.13M |
| Gross profit | 3.80M | 1.08M | 0.50M | - |
| Reconciled depreciation | 0.67M | 0.16M | 0.40M | - |
| Operating income | -13.35M | -15.74M | -15.50M | -17.56M |
| Interest expense | 0.04M | 0.00M | 0.05M | - |
| Tax provision | 0.03M | -0.01M | 0.00M | 0.00M |
| Interest income | 0.04M | 0.01M | 0.06M | 7.48M |
| Net interest income | -0.00M | 0.12M | 0.01M | - |
| Total revenue | 3.80M | 1.22M | 0.56M | 0.90M |
| Total other income expense net | 0.01M | 0.52M | -0.05M | - |
| Net income from continuing ops | -13.37M | -15.24M | -15.55M | - |
| Net income applicable to common shares | - | -15.24M | -15.55M | -25.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 8.96M | 14.20M | 11.57M | 3.10M |
| Intangible assets | 2.90M | 0.02M | 0.01M | 0.01M |
| Other current assets | 0.08M | 0.15M | 0.01M | - |
| Total liab | 4.88M | 3.17M | 0.63M | 30.76M |
| Total stockholder equity | 4.08M | 11.03M | 10.94M | -27.66M |
| Other current liab | 2.02M | 1.09M | - | - |
| Common stock | - | - | - | 58.76M |
| Capital stock | 134.50M | 128.17M | 112.75M | - |
| Retained earnings | -133.74M | -120.37M | -105.13M | -86.64M |
| Good will | 1.84M | 4.33M | - | - |
| Cash | 2.57M | 7.16M | 11.09M | 2.22M |
| Total current liabilities | 4.88M | 2.90M | 0.63M | 30.76M |
| Short term debt | - | - | - | 23.93M |
| Short long term debt | 0.89M | - | - | - |
| Other stockholder equity | - | - | - | 0.21M |
| Property plant equipment | - | - | - | 0.51M |
| Total current assets | 4.08M | 8.69M | 11.44M | 2.57M |
| Net receivables | 0.84M | 0.67M | 0.07M | 0.04M |
| Long term debt | - | 0.20M | - | - |
| Accounts payable | 0.46M | 1.18M | 0.26M | - |
| Non currrent assets other | - | 0.00M | - | - |
| Non current assets total | 4.87M | 5.51M | 0.13M | - |
| Capital lease obligations | 0.01M | 0.11M | - | - |
| Long term debt total | - | - | - | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | - | -3.12M | 0.00M | - |
| Total cashflows from investing activities | - | -3.12M | - | - |
| Net borrowings | 1.49M | - | - | - |
| Total cash from financing activities | 7.71M | 14.45M | 23.72M | - |
| Net income | -13.37M | -15.24M | -15.55M | -25.04M |
| Change in cash | -4.06M | -3.93M | 8.84M | - |
| Begin period cash flow | 7.16M | 11.09M | 2.22M | - |
| End period cash flow | 2.57M | 7.16M | 11.09M | 2.22M |
| Total cash from operating activities | - | -15.17M | - | - |
| Issuance of capital stock | 6.92M | 15.61M | 25.38M | - |
| Other cashflows from investing activities | - | -0.00M | - | - |
| Sale purchase of stock | -0.59M | -1.14M | -1.36M | - |
| Other cashflows from financing activities | - | -0.02M | - | - |
| Capital expenditures | 0.01M | 0.02M | 0.00M | 0.00M |
| Change in working capital | - | 0.12M | - | - |
| Free cash flow | -11.80M | -15.19M | -14.88M | - |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ENL Enlitic Inc |
- -% |
0.03 | - | - | 6.46 | 3.88 | 3.73 | -2.37 |
| PME Pro Medicus Ltd |
-4.52 2.18% |
202.79 | 81.98 | 106.38 | 83.13 | 43.70 | 74.38 | 95.34 |
| 4DX 4DMEDICAL Ltd |
-0.06 2.53% |
2.31 | - | - | 205.57 | 8.53 | 170.03 | -7.29 |
| CGS Cogstate Ltd |
0.12 3.30% |
3.76 | 33.80 | 27.86 | 9.59 | 6.95 | 6.35 | 19.27 |
| AYA ARTRYA Ltd |
-0.14 3.91% |
3.44 | - | - | 20505.14 | 7.00 | 16927.51 | 0.33 |
Enlitic, Inc. operates in the healthcare sector in the United States, Europe, and Japan. The company uses artificial intelligence (AI) to develop software products that manage medical imaging data in radiology, such as magnetic resonance imaging, computed tomography scans, X-ray, and ultrasound images. Its healthcare data solutions include ENDEX, a platform that uses AI to standardize new and historical medical image data descriptions; ENCOG, an AI enabled data anonymization solution designed to de-identify protected health information from medical imaging data; and Migratek, an AI-enabled data migration solution, as well as routing services. The company provides its solutions to radiologists, IT professionals, executives, and researchers; and training services to PACS administrators, IT supervisors, system administrators, radiologists, and technologists. The company was formerly known as You Partners, Inc. Enlitic, Inc. was incorporated in 2014 and is based in Loveland, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Mr. Lawrence B. Gozlan B.Sc., B.Sc.(Hons) | Executive Chairman of the Board | 1979 |
| Mr. Michael Karlgerhard Sistenich B.Sc, M.Sc., MSc | CEO & Director | 1975 |
| Mr. Kevin Lyman | Founder & Chief Science Officer | NA |
| Mr. Darren Scotti | Chief Financial Officer | NA |
| Mr. John Marshall | Chief Operating Officer | NA |
| Mr. Dan Kozimor | Chief Technology Officer | NA |
| Ms. Patty O'Brien | Chief Compliance Officer | NA |
| Mr. Dave Wilson | Vice President of Marketing & Communications | NA |
| Mr. Scott Stanton | Vice President of Sales Operations | NA |
| Mr. Ryan Lennartson | Vice President of People Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.